Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBIn an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
High-Dose Radiation Plus Long-Term ADT Improves Survival in …
WEBJan 25, 2024 · Utilizing a higher dose of radiation therapy in combination with the long-term use of androgen deprivation therapy (ADT) improved survival outcomes after 10 years of follow-up in patients with high-risk prostate cancer, according to long-term results from the GETUG-AFU 18 trial (NCT00967863) presented at …
Breast Cancer | Oncology News & Insights | Targeted Oncology
WEB2 days ago · Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting. Jordyn Sava. July 12th 2024. In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Managing Chemotherapy Toxicities for Improved Patient Outcomes
WEBMar 29, 2021 · In a large majority of patients, even when treating with chemotherapy that is highly emetogenic, nausea and vomiting can be prevented. Options include 5-HT3 receptor antagonists (such as ondansetron), NK-1 receptor antagonists (such as aprepitant), glucocorticoids (such as dexamethasone), and olanzapine, a …
Continuing Osimertinib Treatment After Progression Prolongs …
WEBJan 25, 2019 · The investigators said that continuing osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients. They suggested that further study will be needed, especially given the increasing role for osimertinib in the treatment of EGFR -mutant advanced NSCLC. Reference:
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
WEBDec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
Defining Unresectable and Advanced HCC - Targeted Oncology
WEBJul 20, 2021 · After the approval of sorafenib, we had numerous negative studies, until the REFLECT study. This transcript has been edited for clarity. Richard S. Finn, MD defines unresectable or advanced hepatocellular carcinoma by discussing venous invasion, extrahepatic spread, and progression after locoregional treatments.
Recent Approvals Signal a Bright Future for Myelodysplastic …
WEBDec 22, 2023 · Ivosidenib . In October 2023, ivosidenib (Tibsovo) was cleared by the FDA for the treatment of IDH1-mutated relapsed or refractory MDS, based on findings from the AG120-C-001 trial (NCT02074839).4 In the study, 18 adult patients with relapsed or refractory MDS with an IDH1 mutation received oral ivosidenib daily on a 28-day cycle. All responses in the trial were complete responses (CRs), and ...
FDA Grants Breakthrough Therapy Designation to SNDX-5613 for …
WEBDec 6, 2022 · The FDA has granted a breakthrough therapy designation (BTD) to SNDX-5613 (revumenib) for the treatment of adult and pediatric patients with relapsed or refractory (R/R) acute leukemia harboring a KMT2A rearrangement (KMT2Ar). 1. Phase 1 data from the AUGMENT-101 trial (NCT04065399) support the BTD. In …
Docetaxel Continues to Show Profound Benefits in Prostate Cancer
WEBJan 14, 2017 · In the larger STAMPEDE trial (2962 patients), adding docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer. The median overall survival (OS) was 81 months with docetaxel plus standard of care (hormonal therapy with or …
Skip to content